Anti-human tenascin monoclonal antibody
AssigneeSigma-Tau Industrie Farmaceutiche Riunite S.p.A.
InventorsRita De Santis, Anna Maria Anastasi
Life of this patent
Estimating the term…
Abstract
A novel anti-human tenascin ST2146 monoclonal antibody is described endowed with high affinity for the native antigen and high tumor selectivity. The cST2146 hybridoma is stably producing the antibody in high density culture conditions and is suitable for the industrial development of ST2146-based products. ST2146 exhibits properties exploitable for both therapeutic and diagnostic applications.
Claims33
Monoclonal antibody anti-human tenascin whose light and heavy chain variable region sequences are SEQ ID NO:1 and SEQ ID NO:2, respectively, and the proteolytic fragments thereof binding to an antigenic epitope within the EGF-like repeat of human tenascin C.
Specific CDRs and proteins comprising or containing CDRs.
Dependencies are inferred from the claim text.